U.S., Nov. 22 -- ClinicalTrials.gov registry received information related to the study (NCT07243262) titled 'Volatile Organic Compound Assessment in Pancreatic Ductal Adenocarcinoma (VAPOR2)' on Nov. 17.
Brief Summary: We are developing a non-invasive breath test to help us detect pancreatic cancer earlier. The test detects small molecules called volatile organic compounds that are made by pancreatic cancers.
Pancreatic cancer is a rare disease but patients are often diagnosed at a late stage because their symptoms are the same as those of many common illnesses. This makes it hard for doctors to know which patients need to be tested for pancreatic cancer. If we find pancreatic cancer at a late stage, it reduces the number of treatment cho...